Mesenchymal stromal cell extracellular vesicles improve lung development in mechanically ventilated preterm lambs.

Alveolar formation Bronchopulmonary dysplasia Chronic lung disease of the neonate Exosomes

Journal

American journal of physiology. Lung cellular and molecular physiology
ISSN: 1522-1504
Titre abrégé: Am J Physiol Lung Cell Mol Physiol
Pays: United States
ID NLM: 100901229

Informations de publication

Date de publication:
02 Apr 2024
Historique:
medline: 2 4 2024
pubmed: 2 4 2024
entrez: 2 4 2024
Statut: aheadofprint

Résumé

Novel therapies are needed for bronchopulmonary dysplasia (BPD) because no effective treatment exists. Mesenchymal stromal cell extracellular vesicles (MSC-sEVs) have therapeutic efficacy in a mouse pup neonatal hyperoxia BPD model. We tested the hypothesis that MSC-sEVs will improve lung functional and structural development in mechanically ventilated preterm lambs. Preterm lambs (~129d; equivalent to human lung development at ~28w gestation) were exposed to antenatal steroids, surfactant, caffeine citrate, and supported by mechanical ventilation for 6-7d. Lambs were randomized to blinded treatment with either MSC-sEVs (human bone marrow MSC-derived; 2x10 MSC-sEVs-treated preterm lambs tolerated enteral feedings and maintained weight compared to the vehicle control group. Respiratory severity score, oxygenation index, A-a gradient, distal airspace wall thickness, and smooth muscle thickness around terminal bronchioles and pulmonary arterioles were lower (*) for the MSC-sEVs group versus the vehicle controls. S/F ratio, radial alveolar count, secondary septal volume density, alveolar capillary surface density, and protein abundance of VEGF-R2 were higher (*) for the MSC-sEVs versus the vehicle control group. MSC-sEVs improved respiratory system physiology and alveolar formation in mechanically ventilated preterm lambs. MSC-sEVs may be an effective and safe therapy for appropriate functional and structural development of the lung in preterm infants who require mechanical ventilation and are at-risk of developing BPD.

Sections du résumé

BACKGROUND BACKGROUND
Novel therapies are needed for bronchopulmonary dysplasia (BPD) because no effective treatment exists. Mesenchymal stromal cell extracellular vesicles (MSC-sEVs) have therapeutic efficacy in a mouse pup neonatal hyperoxia BPD model. We tested the hypothesis that MSC-sEVs will improve lung functional and structural development in mechanically ventilated preterm lambs.
METHODS METHODS
Preterm lambs (~129d; equivalent to human lung development at ~28w gestation) were exposed to antenatal steroids, surfactant, caffeine citrate, and supported by mechanical ventilation for 6-7d. Lambs were randomized to blinded treatment with either MSC-sEVs (human bone marrow MSC-derived; 2x10
RESULTS RESULTS
MSC-sEVs-treated preterm lambs tolerated enteral feedings and maintained weight compared to the vehicle control group. Respiratory severity score, oxygenation index, A-a gradient, distal airspace wall thickness, and smooth muscle thickness around terminal bronchioles and pulmonary arterioles were lower (*) for the MSC-sEVs group versus the vehicle controls. S/F ratio, radial alveolar count, secondary septal volume density, alveolar capillary surface density, and protein abundance of VEGF-R2 were higher (*) for the MSC-sEVs versus the vehicle control group.
CONCLUSIONS CONCLUSIONS
MSC-sEVs improved respiratory system physiology and alveolar formation in mechanically ventilated preterm lambs. MSC-sEVs may be an effective and safe therapy for appropriate functional and structural development of the lung in preterm infants who require mechanical ventilation and are at-risk of developing BPD.

Identifiants

pubmed: 38563994
doi: 10.1152/ajplung.00349.2023
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : R01HL146128

Auteurs

Kurt H Albertine (KH)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Andrew Rebentisch (A)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Elaine Dawson (E)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Jakob Van Boerum (J)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Emily Major (E)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Juraj Štipka (J)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Hannah Foreman (H)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

David Headden (D)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Zoë Vordos (Z)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Emily Beck (E)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Zhengming Wang (Z)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Haixia Yang (H)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Baifeng Yu (B)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Mar Janna Dahl (MJ)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Donald M Null (DM)

Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Davide Bizzotto (D)

Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Italy.

Chiara Veneroni (C)

Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, MI, Italy.

Anna Lavizzari (A)

NICU, Fondazione IRCCS Ca' Granda, University of Milan, Milano, Italy.

Raffaele L Dellacà (RL)

Dipartimento di Elettronica, Informatica e Bioingegneria, Politecnico di Milano, Milano, Italy.

Eleni Delavogia (E)

Pediatrics, Boston Children's Hospital, Boston, MA, United States.

S Alex Mitsialis (SA)

Newborn Medicine, Harvard Medical School, Boston, MA, United States.

Stella Kourembanas (S)

Newborn Medicine, Harvard Medical School, Boston, MA, United States.

Classifications MeSH